Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec 12:14:150.
doi: 10.1186/s12905-014-0150-5.

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers

Claudia Marchetti  1 , Francesca De Felice  2 , Innocenza Palaia  3 , Giorgia Perniola  4 , Angela Musella  5 , Daniela Musio  6 , Ludovico Muzii  7 , Vincenzo Tombolini  8 , Pierluigi Benedetti Panici  9
Affiliations
Review

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers

Claudia Marchetti et al. BMC Womens Health. .

Abstract

Background: Women with BRCA1 and BRCA2 mutation carriers are at substantially elevated risk of developing ovarian cancer. The aim of the meta-analysis is to clarify the role of risk-reducing salpingo-oophorectomy (RRSO) to reduce ovarian cancer risk and mortality in women with BRCA 1 and BRCA 2 mutation carriers.

Methods: Pubmed, Medline and Scopus were searched to select English-language articles. Two investigators independently extracted characteristics and results of selected studies. Articles were included only if prospective and if absolute numbers of ovarian cancer and death events were available or derivable from the test. Pooled hazard ratio (HR) with 95% confidence interval (CI) was calculated using fixed effects model.

Results: Meta-analysis of 3 prospective studies demonstrated a significant risk reduction of ovarian cancer with RRSO in BRCA 1 and BRCA 2 mutation carriers, as well as benefit in all-causes mortality incidence.

Conclusions: It may be justified to recommend RRSO to reduce ovarian cancer risk and all-causes mortality in women with a mutation in BRCA 1 and BRCA 2.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of meta-analysis.
Figure 2
Figure 2
Forest plots of relative risk (RR) estimates for risk reduction of ovarian cancer associated with risk-reducing salpingo-oophorectomy in the overall population of BRCA 1 and BRCA 2 mutation carriers.
Figure 3
Figure 3
Forest plots of relative risk (RR) estimates for all-causes mortality associated with risk-reducing salpingo-oophorectomy in the overall population of BRCA 1 and BRCA 2 mutation carriers.
Figure 4
Figure 4
Forest plots of relative risk (RR) estimates for all-causes mortality associated with risk-reducing salpingo-oophorectomy in BRCA 1 and BRCA 2 mutation carriers without prior (a) and with prior breast cancer (b).
Figure 5
Figure 5
Forest plots of relative risk (RR) estimates for risk reduction of ovarian cancer associated with risk-reducing salpingo-oophorectomy in BRCA 1 (a) and BRCA 2 (b) mutation carriers.
Figure 6
Figure 6
Forest plots of relative risk (RR) estimates for all-causes mortality associated with risk-reducing salpingo-oophorectomy in BRCA 1 (a) and BRCA 2 (b) mutation carriers.
See this image and copyright information in PMC

References

    1. Bougie O, Weberpals JI. Clinical considerations of BRCA1- and BRCA2- mutation carriers: a review. Int J Surg Oncol. 2011;2011:374012. - PMC - PubMed
    1. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646. doi: 10.1126/science.1088759. - DOI - PubMed
    1. Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2009), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. [released April 2012 based on November 2011 submission]. Available at: www.seer.cancer.gov.
    1. National Comprehensive Cancer Network (NCCN): Genetic High-Risk familial Assessment: Breast and Ovarian. 2013; 4:2013. [Available from: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf]
    1. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185–192. doi: 10.1001/jama.296.2.185. - DOI - PubMed